언택트 시대의 연하장애 디지털 헬스케어

서울대학교병원 재활의학과 이우형



Contents

- What is digital health?
 - Spectrum
 - Categories

Digital health in dysphagia


• Issues in digital health



COVID-19 era




Medicine in COVID-19 era



Non-Face-to-Face medical care




Non-Face-to-Face medical care







In rehabilitation medicine ...







Conventional dysphagia evaluation and treatment




TABLE 18.4 Options for the Treatment of Dysphagia

Compensatory treatments

Postural adjustments

Diet modification

Change of eating habits

Feeding strategies

Rehabilitative treatments

Strengthening exercises

Range-of-motion exercises

Sensory enhancement

Surgical treatments

Correction of structural abnormalities

Treatment of vocal cord paralysis

Cricopharyngeal myotomy or UES dilatation^a

Gastrostomy (most often percutaneous)


Therapies under evaluation


Transcranial magnetic stimulation Implantable neuroprosthesis

*Only indicated in cases of isolated cricopharyngeal muscle dysfunction, in which this muscle and the UES fail to relax upon swallowing (can be seen as part of the lateral medullary syndrome).—Abbreviation: UES, upper esophageal sphincter.



Digital health







DIGITAL HEALTH

DIGITAL MEDICINE

DIGITAL THERAPEUTICS

DEFINITION	Digital health includes technologies, platforms, and systems that engage consumers for lifestyle, wellness, and health-related purposes; capture, store or transmit health data; and/or support life science and clinical operations.	Digital medicine includes evidence-based software and/or hardware products that measure and/or intervene in the service of human health.1	Digital therapeutic (DTx) products deliver evidence-based therapeutic interventions to prevent, manage, or treat a medical disorder or disease. ²	
CLINICAL EVIDENCE	Typically do not require clinical evidence.	Clinical evidence is required for all digital medicine products.	Clinical evidence and real world outcomes are required for all DTx products.	
REGULATORY OVERSIGHT These products do not meet the regulatory definition of a medical device ³ and do not require regulatory oversight.		Requirements for regulatory oversight vary. Digital medicine products that are classified as medical devices require clearance or approval. Digital medicine products used as a tool to develop other drugs, devices, or medical products require regulatory acceptance by the appropriate review division.	DTx products must be reviewed and cleared or certified by regulatory bodies as required to support product claims of risk, efficacy, and intended use.	

¹ https://www.dimesociety.org/index.php/defining-digital-medicine

² https://www.dtxalliance.org/dtxproducts/

³ It is important to check with local regulatory requirements in each jurisdiction the product is manufactured, registered, or used in.

DIGITAL HEALTH

DIGITAL MEDICINE

DIGITAL THERAPEUTICS

DEFINITION	Digital health includes technologies, platforms, and systems that engage consumers for lifestyle, wellness, and health-related purposes; capture, store or transmit health data; and/or support life science and clinical operations.	Digital medicine includes evidence-based software and/or hardware products that measure and/or intervene in the service of human health. ¹	Digital therapeutic (DTx) products deliver evidence-based therapeutic interventions to prevent, manage, or treat a medical disorder or disease. ²
CLINICAL EVIDENCE	Typically do not require clinical evidence.	Clinical evidence is required for all digital medicine products.	Clinical evidence and real world outcomes are required for all DTx products.
REGULATORY OVERSIGHT	These products do not meet the regulatory definition of a medical device ³ and do not require regulatory oversight.	Requirements for regulatory oversight vary. Digital medicine products that are classified as medical devices require clearance or approval. Digital medicine products used as a tool to develop other drugs, devices, or medical products require regulatory acceptance by the appropriate review division.	DTx products must be reviewed and cleared or certified by regulatory bodies as required to support product claims of risk, efficacy, and intended use.

¹ https://www.dimesociety.org/index.php/defining-digital-medicine

² https://www.dtxalliance.org/dtxproducts/

³ It is important to check with local regulatory requirements in each jurisdiction the product is manufactured, registered, or used in.

DIGITAL HEALTH

DIGITAL MEDICINE

DIGITAL THERAPEUTICS


DEFINITION	Digital health includes technologies, platforms, and systems that engage consumers for lifestyle, wellness, and health-related purposes; capture, store or transmit health data; and/or support life science and clinical operations.	Digital medicine includes evidence-based software and/or hardware products that measure and/or intervene in the service of human health.1	Digital therapeutic (DTx) products deliver evidence-based therapeutic interventions to prevent, manage, or treat a medical disorder or disease. ²
CLINICAL EVIDENCE	Typically do not require clinical evidence.	Clinical evidence is required for all digital medicine products.	Clinical evidence and real world outcomes are required for all DTx products.
REGULATORY OVERSIGHT	These products do not meet the regulatory definition of a medical device ³ and do not require regulatory oversight.	Requirements for regulatory oversight vary. Digital medicine products that are classified as medical devices require clearance or approval. Digital medicine products used as a tool to develop other drugs, devices, or medical products require regulatory acceptance by the appropriate review division.	DTx products must be reviewed and cleared or certified by regulatory bodies as required to support product claims of risk, efficacy, and intended use.

¹ https://www.dimesociety.org/index.php/defining-digital-medicine


² https://www.dtxalliance.org/dtxproducts/

³ It is important to check with local regulatory requirements in each jurisdiction the product is manufactured, registered, or used in.

Categories of digital health



(1) Data





(2) Device



Samsung smartphone



Apple watch




Xiaomi Mi Scale



Beddit, sleep tracker



FreeStyle Libre, glucose monitoring





(3) Machine learning

- How machine learning can augment the work of clinicians?
 - Prognosis
 - Diagnosis
 - Treatment
 - Clinician workflow
 - Expanding the availability of clinical expertise







Figure 1. Hierarchy of artificial intelligence-related terms.



(4) Telemedicine

- What is telemedicine?
 - The remote diagnosis and treatment of patients by means of tele-communications technology
- Telemedicine encompasses the use of technologies and tele-communication systems to administer healthcare to patients who are geographically separated from providers
- Tele-monitoring ~ Tele-surgery






Fig. 2 | Integrated system of digital health technologies in a possible future rheumatology clinic. Patients will use smartphone apps with or without voice-enabling capacity to report symptoms to their clinicians. Their symptoms may be reported as electronic patient-reported outcomes (ePROs) through the electronic health record (EHR). The information from the EHR and other data sources will be integrated in a centralized and secure server environment. Machine learning and artificial intelligence algorithms will be running against the data to assist clinicians with diagnosis, prognosis, treatment selection and monitoring.




「한시적 비대면 진료 허용방안」 안내

- 고로나바이러스감염증-19 중앙사고수습본부-32695(2020.12.14)호와 관련, 「감염병의 예방 및 관리에 관한 법률」(국무회의 의결, 12.8) 및 2020년 제4차 감염병관리위원회 심의・ 의결에 따라, 코로나19 감염병 위기대응 심각단계시 「한시적 비대면 진료 허용방안」을 마련하고, 붙임과 같이 공고합니다.
- ◆ '코로나19 감염병 위기대응 심각단계의 위기경보 발령 기간' 동안
 - 의사의 판단에 따라 안전성 확보가 가능한 경우 환자가 의료 기관을 직접 방문하지 않고도 비대면 진료를 받을 수 있도록 한시적으로 허용
 - ◇ (적용 기간) 코로나 19 감염병 위기대응 심각 단계의 위기경보 발령 기간(「감염병의 예방 및 관리에 관한 법률」 제49조의3 공포 시행일(*20.12.15)부터 적용)
 - ◇ (적용 범위) 유·무선 전화, 화상통신을 활용한 상담 및 처방* 진료의 질을 보장하기 위하여 문자메시지, 메신저만을 이용한 진료는 불가



Digital health in dysphagia





Image(VFSS) + Machine learning




Fig. 2 – The axes for kinematic analysis of videofluoroscopic images. The Y-axis was set to a line connecting the anterior edges of C4 and C2 lower endplates, and then a line perpendicular to the Y-axis at C4's lower endplate constitutes the X-axis. A radio-opaque disc was attached under the chin (arrowheads) to measure distance of movement. Asterisk (*) indicates the anterosuperior end of hyoid bone.





Image (VFSS) + Machine learning






Table 3. Performance per frame for classifying airway invasion.

Accuracy	Recall	Precision	Specificity	NPV	F1-Score
97.2%	74.2%	59.1%	98.0%	99.0%	0.658

Table 4. Performance for classifying complete videos containing image frames with airway invasion.

Accuracy	Recall	Precision	Specificity	NPV
93.2%	91.2%	88.1%	94.2%	95.8%
(167/179)	(52/57)	(52/59)	(115/122)	(115/120)

IMU sensor (accelerometer) & microphone





Fig. 1 Transducer mounting locations. Location of recording devices during data collection. A: Thyroid cartilage B: top of the suprasternal notch For reference, the microphone (lower device) is approximately 10 × 30 mm and the accelerometer (upper device) is aligned with the centre axis of the neck. This figure has been previously published by BioMed Central in [41]

Feature	A-P	S-I	Sound
Skewness	p << 0.001	p << 0.001	p << 0.001
Kurtosis	p << 0.001	p << 0.001	p << 0.001
Entropy rate	p << 0.001	p << 0.001	p << 0.001
L-Z complexity	p << 0.001	p << 0.001	p << 0.001
Peak frequency	p << 0.001	p << 0.001	p << 0.001
Center frequency	p << 0.001	p << 0.001	p << 0.001
Bandwidth	p << 0.001	p << 0.001	p << 0.001
Wavelet entropy	p << 0.001	p << 0.001	p << 0.001




Microphone + Machine learning



a food particle in it

91 % sensitivity and 85 % specificity in detection of patients with severe aspiration






Image (VFSS) + Telemedicine







Fig. 3. A CAC screen in the PI's laboratory during live image transmission.

Table 2. Recommendation groups, number of discrepancies/disagreements, percentage of agreement, and 95% confidence intervals (Cls) for the percentage of agreement.

	Number of		95% CI for the percentage of agreement	
Recommendation group	discrepancies/disagreements	% agreement	Upper bound	Lower bound
Reducing or eliminating oral intake	7/32	78.1	0.89	0.61
Altering meal habits	10/32	68.8	0.82	0.51
Medication administration method	1/32	96.9	1.00	0.84
Control bolus viscosity	6/32	81.2	0.91	0.65
Postural adjustments	5/32	84.4	0.93	0.68
Laryngeal closure maneuvers and exercises	4/32	87.5	0.95	0.72
Strengthening and ROM exercises and maneuvers	2/32	93.7	0.98	0.80
Sensory enhancement	0/32	100	1.00	0.89
Referral to physicians	6/32	81.2	0.91	0.65



Microphone & Smartphone + Telemedicine






Fig. 2. Comparison of the swallowing sound with the corresponding videofluoroscopic images.



Image + Machine learning + Personalized treatment + Telemedicine

Action Sequence	Common Errors	System Requirement (sysreq)
		1. Detect nearby face in view of camera (determine when to initiate monitoring)
Sit in upright position	Head/trunk misaligned	2. Estimate head/trunk alignment
Sip liquid/spoon in food	Swallow before tuck	3. Track cup/utensil movement toward and into mouth.
Tuck chin to chest	Forget to perform tuck Incomplete tuck Swallow mid-tuck	4. Estimate head/angle to torso in sagittal plane
Swallow in that position	Raise head during swallow	5. Detect swallow (timing and omission errors)
Raise the head	Swallow post tuck	
Table 1. Chin Tuck Actions of	and Errors	








Image + Personalized treatment + Telemedicine

Lee Silverman Voice Treatment (LSVT)

REPORTED REPORTED REPORTED & HYPOTHESED SPEECH PHYSIOLOGICAL SWALLOW/COUGH CHANGES [23] CHANGES [23] CHANGES Articulatory precision Articulatory movements Lingual function [28] Speech intelligibility Vocal tract configuration Tongue base strength [28] Prosodic inflection Laryngeal & supralaryngeal movements Pharyngeal timing & strength [28,50*] Resonance Airway closure [28,50*] Voice quality Vocal fold adduction Laryngeal muscle activity & synergy Respiratory drive Expiratory cough [47-50*] Loudness

*Changes seen with forced expiratory exercises (EMST)








Face-to-face interaction


LSVT education
Personal relationship
Homework tasks



A clinician certified in LSVT

Personalized management + Machine learning





Wellness device vs. Medical device


Wellness device

- 일상적 건강관리용
- 만성질환자 건강관리용

Medical device


- 질병을 진단, 치료, 경감, 처치 또는 예방할 목적으로 사용하는 제품
- 상해 또는 장애를 진단, 치료, 경감 또는 보정할 목적으로 사용하는 제품
- 구조 또는 기능을 검사 대체 또는 변형할 목적으로 사용하는 제품
- 임신을 조절할 목적으로 사용하는 제품


Digital therapeutics












507 patients with Substance Use Disorder at 10 nationwide treatment centers were randomized to 12 weeks of typical outpatient treatment (TAU) vs reSET® with limited clinician exposure and abstinence was measured through urine analysis and self reports¹



Population	Time Point	reSET® (n=255)		Odds Ratio (95% CI)	P-value*
All comers	Week 9-12	29.7%	16.0%	2.22 (1.24, 3.99)	0.0076
Non-abstinent at start	Week 9-12	10.1%	3.0%	3.59 (1.36, 9.48)	0.0099

¹ Campbell et al. Am J Psychiatry. 2014.


Table 1. Sampling	the Digital Therape	utics Pipeline.			
Company	Product	Indication(s)	Status	Commercial partner	Investment partner
Pear Therapeutics	reSET	Substance use disorder ^{25,26}	Marketed	Sandoz ^{a27}	Novartis
	reSET-O	Opioid use disorder ²⁸	Marketed	Sandoz ^a	
	Somryst	Chronic insomnia ²⁹	Marketed		
	Pear-004	Schizophrenia	Marketed ^b Pivotal		
	Pear-006	Multiple sclerosis	Discovery	Novartis ³⁰	
	Unspecified	Gastrointestinal conditions	Discovery	Ironwood Pharmaceuticals ³¹	
Welldoc	Bluestar	Type I diabetes, Type II diabetes ³²	Marketed	Astellas ³³	
Akili Interactive	Endeavor	ADHD ³⁴	Marketed	Shionogi ³⁵	Amgen, Merck
	AKL-T02	Autism spectrum disorder ³⁶	Pilot		
	AKL-T03	Major depressive disorder	Pilot		
Nightware	Nightware	Post-traumatic stress disorder	Marketed		
Click Therapeutics	CT-152	Major depressive disorder	Pivotal	Otsuka ³⁷	Sanofi, Hikma
Cognoa	Autism Diagnostic	Autism spectrum disorder	Pivotal	EVERSANA	
	Autism Therapeutic	Autism spectrum disorder ³⁸	Feasibility		
Biofourmis	BiovitalsHF V1	Heart failure	Marketed	Novartis ³⁹	
	BiovitalsHF V2	Heart failure ⁴⁰	Pivotal		
	BF140	Pain ⁴¹	Pilot	Chugai ⁴²	
Propeller Health	Propeller	Asthma ⁴³ , chronic obstructive pulmonary disease ⁴⁴	Marketed	AstraZeneca ⁴⁵ , GlaxoSmithKline, Novartis, Orion, Boehringer Ingelheim	
AppliedVR	EaseVRx	Chronic pain ⁴⁶	Efficacy		
	RelieVRx	Acute postoperative pain ⁴⁷	Efficacy		
	AnxietyVRx	Generalized anxiety	Discovery		
Happify Health	Happify	Multiple sclerosis-associated depression and anxiety	Discovery	Sanofi ⁴⁸	
As of November 201	20				

As of November 2020.



^aDissolved partnership.
^bMarketed temporarily under the FDA Enforcement Policy for Digital Health Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency.

Process for evaluating a novel health technology



Clinical evaluation

SaMD N41 Clinical Evaluation

Clinical Association

between a SaMD output and a Clinical Condition

Literature searches, Original Clinical Research, Professional Society Guidelines, Secondary Data Analysis, Clinical Trials

Product Performance

Verify & Validate

Analytical / Technical Validation

Accuracy, Reliability, Precision...

Clinical Validation

Sensitivity, Specificity, Odds Ratio...

SaMD Definition Statement

- Intended Medical Purpose of a SaMD
- Treat or Diagnose
- Drive Clinical Management
- Inform Clinical Management
- Targeted Healthcare Situation or Condition of a SaMD
 - Critical
 - Serious
 - Non-Serious

SaMD Categories

	Treat or Diagnose	Drive Clinical Mgmt	Inform Clinical Mgmt
Critical	IV	III	II
Serious	III	II	I
Non- Serious	II	I	I

SaMD N12 Risk Categorization Framework

Requirements, Design, Develop, Verify & Validate.
Deploy, Maintain, Retire

SaMD Realization and Use Processes

Planning, **Risk Management**, Documentation, Configuration, Measurement, Outsourcing

SaMD Lifecycle Support Processes

Personnel, Infrastructure, Work Environment

Leadership and Organizational Support

SaMD N23 Quality Management System

Regulation







Regulation

제34조(원격의료)

- ①의료인(의료업에 종사하는 의사・치과의사・한의사만 해당한다)은 제33조제1항에도 불구하고 컴퓨터・화상통신 등 정보통신기술을 활용하여 **먼 곳에 있는 의료인에게 의료지식** 이나 기술을 지원하는 원격의료(이하 "원격의료"라 한다)를 할 수 있다.
- ⊜원격의료를 행하거나 받으려는 자는 보건복지부령으로 정하는 시설과 장비를 갖추어야 한다. <개정 2008. 2. 29., 2010. 1. 18.>
- ⊛원격의료를 하는 자(이하 "원격지의사"라 한다)는 환자를 직접 대면하여 진료하는 경우와 같은 책임을 진다.
- ④원격지의사의 원격의료에 따라 의료행위를 한 의료인이 의사 치과의사 또는 한의사(이하 "현지의사"라 한다)인 경우에는 그 의료행위에 대하여 원격지의사의 과실을 인정할 만한 명백한 근거가 없으면 환자에 대한 책임은 제3항에도 불구하고 현지의사에게 있는 것으로 본다.



Summary

- Spectrum of digital health
 - Digital health medicine therapeutics
- Categories of digital health
 - Data
 - Sensors
 - IT (mobile)
 - Personalized care
 - Telehealth

- Digital medicine in dysphagia
 - No commercial services
 - Usually focused on component technologies
 - Automatic evaluation based on ML
 - Data acquisition with wearable sensors
 - Telemedicine (mobile IT)
 - Personalized medicine
- Issues



Thank you

